Meropenem - Pfizer/Sumitomo Dainippon Pharma

Drug Profile

Meropenem - Pfizer/Sumitomo Dainippon Pharma

Alternative Names: ICI 194660; ICI 213689; Mepem; Meronem; Meropen; Merozen; Merrem; Optinem; SM-7338; Zeropenem®

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Chiesi Farmaceutici; PENTA Foundation; Pfizer; Sanofi; Sumitomo Dainippon Pharma
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Febrile neutropenia; Skin and soft tissue infections
  • Discontinued Bacterial meningitis; Sepsis

Most Recent Events

  • 24 Aug 2016 AstraZeneca plans to sell the commercialisation and development rights to late-stage small molecule antibiotics to Pfizer
  • 15 Mar 2016 Biomarkers information updated
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top